ProfileGDS5678 / 1460277_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 36% 36% 37% 34% 33% 34% 36% 36% 36% 48% 35% 35% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8500536
GSM967853U87-EV human glioblastoma xenograft - Control 22.8215336
GSM967854U87-EV human glioblastoma xenograft - Control 32.8206436
GSM967855U87-EV human glioblastoma xenograft - Control 42.7844337
GSM967856U87-EV human glioblastoma xenograft - Control 52.7295134
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8324733
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8264934
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8106836
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8002136
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.809736
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1426448
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7700635
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8111535
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8339837